Clinical trial · Interventional
Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer
Phase III Randomized Trial of Sequential High-Dose Chemotherapy Versus Standard Chemotherapy for the Treatment of Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell transplant or bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known whether high-dose chemotherapy plus peripheral stem cell or bone marrow transplant is more effective than chemotherapy alone in treating small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well chemotherapy followed by peripheral stem cell or bone marrow transplant works compared to chemotherapy alone in treating patients with limited-stage or extensive-stage small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous bone marrow transplantation | Procedure | — | UNRESOLVED |
| bone marrow ablation with stem cell support | Procedure | — | UNRESOLVED |
| carboplatin | Drug | Carboplatin | ALIAS |
| epirubicin hydrochloride | Drug | Epirubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| etoposide phosphate | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| ifosfamide | Drug | Ifosfamide | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (OS) at 3 years
Secondary outcomes (3)
- measure
- Progression-free survival (PFS) at 3 years
- measure
- Toxicity at 3 years
- measure
- Quality of life (QOL) at 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed small cell lung cancer * Limited disease or extensive disease with no more than 2 metastatic sites * No CNS metastasis PATIENT CHARACTERISTICS: Age: * 65 and under Performance status: * ECOG 0-1 Life expectancy: * Not specified Hematopoietic: * WBC at least 3,500/mm\^3 OR * Platelet count greater than 100,000/mm\^3 OR * Hemoglobin at least 10.0 g/dL Hepatic: * AST/ALT less than 2.5 times upper limit of normal (ULN) * Alkaline phosphatase less than 2.5 times ULN * Bilirubin less than 2.5 times ULN Renal: * Creatinine clearance at least 60 mL/min * No renal function that would preclude chemotherapy Cardiovascular: * No congestive heart failure * LVEF at least 50% * No cardiac function that would preclude chemotherapy Other: * No other malignancy within the past 3 years except for basal cell skin cancer or carcinoma in situ of the cervix * No psychiatric disorder or any other disorder that would preclude study participation * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy Surgery: * Not specified
References
Publications (0)
Data not yet available